Get started
Author

Lukas Owens

Observed name: Owens, Lukas
ORCID: 0000-0002-5149-5379
Observed ORCID: 0000-0002-5149-5379
OpenAlex ID: A5015883299
Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests
2022 · Lukas Owens, Roman Gulati, et al. · Cancer Epidemiology Biomarkers & Prevention · 52
PDF
Survival in Patients With De Novo Metastatic Prostate Cancer
2024 · Martin W. Schoen, R. Bruce Montgomery, et al. · JAMA Network Open · 27
PDF
Trends in young-onset cancer incidence: a modeling perspective
2025 · Lukas Owens, Allison Fung, et al. · JNCI Journal of the National Cancer Institute · 14
PDF
Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019
2024 · Lukas Owens, Ojas Brahme, et al. · JNCI Cancer Spectrum · 10
Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective
2026 · Kemal C. Gogebakan, Natalia Kunst, et al. · Journal of Nuclear Medicine · 7
Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points
2025 · Kemal Caglar Gogebakan, Jane Lange, et al. · JAMA Network Open · 7
PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617
2026 · Alireza Ghodsi, Lukas Owens, et al. · Radiology · 5
Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel
2024 · Trent Irwin, Amelia W. Donlan, et al. · Human Pathology · 5
Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?
2023 · Lukas Owens, Kemal Caglar Gogebakan, et al. · Cancer Epidemiology Biomarkers & Prevention · 4
PDF
Survival trends in de novo metastatic prostate cancer: SEER and Veterans Affairs comparison.
2023 · Martin W. Schoen, Lukas Owens, et al. · Journal of Clinical Oncology · 3
Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group
2026 · Roman Gulati, Krithika Suresh, et al. · Cancer · 1
Measuring and defining screening benefit in a new era of cancer early detection
2026 · Ruth Etzioni, Kemal Gogebakan, et al. · JNCI Journal of the National Cancer Institute · 1
Prostate‐specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long‐term survival
2025 · Kemal Caglar Gogebakan, Zizi Elsisi, et al. · Cancer · 1
Reply to “Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses”
2026 · Kemal C. Gogebakan, Natalia Kunst, et al. · Journal of Nuclear Medicine
PDF
Dynamic Predictions and Predictimands for Salvage Therapy in Recurrent Prostate Cancer Using Joint Models
2026 · Lukas Owens, Dimitris Rizopoulos, et al. · Statistics in Medicine
PDF
Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate
2026 · Martin W. Schoen, Jiannong Li, et al. · JCO Precision Oncology
PDF
TrajSurv-mPC: Learning From Prostate-Specific Antigen Trajectories for Interpretable and Generalizable Survival Prediction in Metastatic Prostate Cancer
2026 · Sihang Zeng, Lukas Owens, et al. · JCO Clinical Cancer Informatics
STRATOS-P clinical model for prognosis and selection of patients with metastatic hormone sensitive prostate cancer (mHSPC) for intermittent therapy.
2026 · Martin W. Schoen, Joshua Gruber, et al. · Journal of Clinical Oncology
Abstract LB006: Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to 177Lu-PSMA-617 therapy
2026 · Arthur P. McDeed, Robert Patton, et al. · Cancer Research
Abstract A011: Early Onset Cancer Incidence: A Model for the Role of Diagnostic Advances
2025 · Ruth D. Etzioni, Lukas Owens · Clinical Cancer Research
Learning from prostate cancer statistics
2025 · Ruth Etzioni, Lukas Owens · CA A Cancer Journal for Clinicians
Abstract 2316: Young-onset cancer incidence trends: Cohort effects on onset versus period effects on diagnosis
2025 · Lukas Owens, Jonathan Shuhendler, et al. · Cancer Research
Ip26-01 Dynamic Predictions to Inform Salvage Therapy Decisions in Men With Biochemical Recurrence After Radical Prostatectomy
2025 · Lukas Owens, Jonathan Fainberg, et al. · The Journal of Urology
PDF
TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC.
2024 · Jessica E. Hawley, Lukas Owens, et al. · Journal of Clinical Oncology
Trends in diagnosis of de novo metastatic hormone sensitive prostate cancer in US Veterans, 2002-2021.
2023 · Nada Al masalmeh, Ruth Douglas Etzioni, et al. · Journal of Clinical Oncology
PDF
Works count: 27
Citation count: 137
H-index: 6
I10-index: 4
Year
Topic
Type